Jason Butler
Stock Analyst at JMP Securities
(3.35)
# 927
Out of 4,902 analysts
146
Total ratings
43.45%
Success rate
4.2%
Average return
Main Sectors:
Stocks Rated by Jason Butler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RAPP Rapport Therapeutics | Reiterates: Market Outperform | $28 | $14.84 | +88.68% | 2 | Jul 8, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Market Outperform | $37 | $22.55 | +64.08% | 14 | Jun 26, 2025 | |
| GHRS GH Research | Reiterates: Market Outperform | $39 | $17.25 | +126.09% | 5 | Jun 24, 2025 | |
| PGEN Precigen | Reiterates: Market Outperform | $6 | $1.82 | +229.67% | 11 | Jun 12, 2025 | |
| PRTA Prothena Corporation | Maintains: Market Outperform | $78 → $29 | $6.47 | +348.22% | 10 | May 27, 2025 | |
| VIGL Vigil Neuroscience | Downgrades: Market Perform | n/a | $8.08 | - | 5 | May 22, 2025 | |
| TTD The Trade Desk | Maintains: Market Outperform | $115 → $100 | $81.44 | +22.79% | 1 | May 9, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Market Outperform | $42 → $38 | $17.05 | +122.87% | 8 | May 7, 2025 | |
| ABVX ABIVAX Société Anonyme | Reiterates: Market Outperform | $33 | $10.34 | +219.15% | 3 | Apr 30, 2025 | |
| CYTK Cytokinetics | Reiterates: Market Outperform | $78 | $38.89 | +100.57% | 16 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $17 → $18 | $12.66 | +42.18% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $1.24 | +222.58% | 7 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $696 → $701 | $572.71 | +22.40% | 8 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $29 → $33 | $10.67 | +209.28% | 1 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $8 → $9 | $5.54 | +62.45% | 8 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $72 → $73 | $57.81 | +26.29% | 13 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $9 | $4.37 | +105.95% | 7 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.40 | - | 7 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $50 → $23 | $1.14 | +1,917.54% | 3 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $11.07 | +71.64% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $22 | $0.79 | +2,681.99% | 1 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.99 | - | 1 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $42,000 | $8.74 | +480,449.20% | 1 | Dec 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $111 → $116 | $7.23 | +1,504.43% | 4 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $9 | $3.14 | +186.62% | 1 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.48 | - | 1 | Dec 2, 2020 |
Rapport Therapeutics
Jul 8, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $14.84
Upside: +88.68%
ACADIA Pharmaceuticals
Jun 26, 2025
Reiterates: Market Outperform
Price Target: $37
Current: $22.55
Upside: +64.08%
GH Research
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $39
Current: $17.25
Upside: +126.09%
Precigen
Jun 12, 2025
Reiterates: Market Outperform
Price Target: $6
Current: $1.82
Upside: +229.67%
Prothena Corporation
May 27, 2025
Maintains: Market Outperform
Price Target: $78 → $29
Current: $6.47
Upside: +348.22%
Vigil Neuroscience
May 22, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $8.08
Upside: -
The Trade Desk
May 9, 2025
Maintains: Market Outperform
Price Target: $115 → $100
Current: $81.44
Upside: +22.79%
Viridian Therapeutics
May 7, 2025
Maintains: Market Outperform
Price Target: $42 → $38
Current: $17.05
Upside: +122.87%
ABIVAX Société Anonyme
Apr 30, 2025
Reiterates: Market Outperform
Price Target: $33
Current: $10.34
Upside: +219.15%
Cytokinetics
Apr 10, 2025
Reiterates: Market Outperform
Price Target: $78
Current: $38.89
Upside: +100.57%
Mar 12, 2025
Maintains: Market Outperform
Price Target: $17 → $18
Current: $12.66
Upside: +42.18%
Mar 5, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $1.24
Upside: +222.58%
Feb 28, 2025
Maintains: Outperform
Price Target: $696 → $701
Current: $572.71
Upside: +22.40%
Feb 21, 2025
Maintains: Market Outperform
Price Target: $29 → $33
Current: $10.67
Upside: +209.28%
Feb 13, 2025
Maintains: Market Outperform
Price Target: $8 → $9
Current: $5.54
Upside: +62.45%
Nov 1, 2024
Maintains: Market Outperform
Price Target: $72 → $73
Current: $57.81
Upside: +26.29%
Oct 8, 2024
Reiterates: Market Outperform
Price Target: $9
Current: $4.37
Upside: +105.95%
Sep 4, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $0.40
Upside: -
Jul 26, 2024
Maintains: Market Outperform
Price Target: $50 → $23
Current: $1.14
Upside: +1,917.54%
Apr 9, 2024
Reiterates: Market Outperform
Price Target: $19
Current: $11.07
Upside: +71.64%
Sep 28, 2023
Initiates: Market Outperform
Price Target: $22
Current: $0.79
Upside: +2,681.99%
Oct 17, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.99
Upside: -
Dec 15, 2021
Initiates: Market Outperform
Price Target: $42,000
Current: $8.74
Upside: +480,449.20%
Nov 23, 2021
Maintains: Market Outperform
Price Target: $111 → $116
Current: $7.23
Upside: +1,504.43%
Nov 8, 2021
Maintains: Market Outperform
Price Target: $7 → $9
Current: $3.14
Upside: +186.62%
Dec 2, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $0.48
Upside: -